“End-to-End” Strategies Achieve Better Enrollment, Diversity, and Data Collection in Clinical Trials
The revolution in cancer drug development has a caveat: Only a fraction of eligible patients take part in clinical trials. Historically, findings from studies estimate that the share of eligible ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback